drugset / Trial / NCT02775773

Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH

NCT02775773

Phase 3 Completed 256 enrolled Azienda U.S.L. 1 di Massa e Carrara
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate that the tranexamic acid (TXA)Intravenous and oral, is equivalent oxytocin (OXY),intramuscularly, in reducing the blood loss in post partum period (mL) in patients at the end of pregnancy ( 37-42 w ) at low risk of post partum hemorrhage (PPH). The PPH means a blood loss equal to or greater than 500 ml after a vaginal delivery (the bleeding is defined severe if it exceeds 1000 mL). PPH is called "primary" when blood loss arose within 24 hours after birth.

Timeline

Start
2018-01-30
Primary completion
2018-12-31
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxytocin Peptide 10 iu Intramuscular
Subject Tranexamic Acid Small molecule 1 g Intravenous

Indications

No indication recorded.